Scienture Holdings earnings release, August 20, 2026

Scienture Holdings, Inc. (SCNX) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

SCIENTURE

Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Q2

2026 Gross Margin Was Approximately 97.7%, Reflecting the Company’s Growing Commercial Revenue Base

Q2

2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million

Q2

2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million

Commenced

Commercial Launch of REZENOPY™, Establishing the Company’s Second Commercial Product and Expanding Its Revenue-Generating

Portfolio

COMMACK,

NY, Aug. 14, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three and six months ended June 30, 2026.

Second

Quarter 2026 and First Half 2026 Financial Highlights

Key

Operational Highlights in Q2 2026 and Subsequent Events:

Narasimhan

Mani, President, Interim CFO, and Co-CEO of Scienture, commented, “We believe our second-quarter results demonstrate that Scienture has reached an important inflection point. Revenue for Q2 20226 increased about 510% sequentially, from approximately $56,000 in the first quarter to approximately $344,000 in the second quarter. At the same time, we generated gross margins of approximately 98%, reduced operating expenses by about 41% year-over-year and narrowed our net loss by approximately 58%. We also ended the quarter with approximately

$11.2 million in cash, cash equivalents and restricted cash, compared with about $6.7 million at year-end 2025, providing us with a stronger financial position as we execute the next phase of our commercial growth strategy. We believe these results demonstrate that we are on the right path to deliver value added business growth in the coming quarters and that we are beginning to realize the operating leverage we have been working toward.”

“Arbli’s continued commercial progress gives us confidence in our ability to build and scale differentiated pharmaceutical products, and we believe we have only begun to realize its market opportunity,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “We are expanding payer access and commercial availability for Arbli™ while simultaneously bringing REZENOPY™ online commercially in the third quarter of 2026. With Arbli™ continuing to gain traction and REZENOPY™ becoming our second commercial-stage product, we believe Scienture is positioned to meaningfully accelerate top-line revenue growth during the second half of 2026 and into 2027. With two differentiated FDA-approved products, approximately 98% gross margins, a strengthened cash position and a more disciplined operating expense structure, we believe we have turned an important corner and established a clear path toward our goal of achieving profitability in 2027.”

About

Arbli™

Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.

INDICATION

Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:

IMPORTANT

SAFETY INFORMATION

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also contact Scienture at 1-833-754-4917.

Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.

About

Hypertension

Hypertension

(high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher.

Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic... (truncated)he diastolic blood pressure readings on both days is ≥ 90 mmHg.

About

REZENOPY™

REZENOPY™

(naloxone hydrochloride) Nasal Spray 10mg, is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. REZENOPY™ nasal spray is not a substitute for emergency medical care. If the desired response is not obtained after 2 to 3 minutes, administer a second dose of REZENOPY™ nasal spray using a new REZENOPY™ nasal spray device. If there is still no response and additional doses are available, administer additional doses of REZENOPY™ every 2 to 3 minutes, alternating nostrils and using a new REZENOPY™, until emergency medical assistance arrives. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance

REZENOPY™ nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.

IMPORTANT

SAFETY INFORMATION

REZENOPY™

(naloxone hydrochloride) Nasal Spray 10 mg is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present and is not a substitute for emergency medical care.

Important

Safety Information

For complete product information, including Patient Information, please refer to the full Prescribing Information.

About

Scienture Holdings, Inc.

SCIENTURE

HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary

Financial statements

Income Statement

Three Months Ended — (Unaudited)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Revenues343,639$-399,96410,258
Cost of sales7,86010,3359,585
Gross profit335,779389,629673
Operating expenses:Wage and salary expense411,411773,739831,4191,469,807
Operating expenses:Professional fees963,752209,7631,896,304622,613
Operating expenses:Accounting and legal expense117,815381,683443,993852,508
Operating expenses:Technology expense7,13921,40822,90283,028
Operating expenses:General and administrative368,7902,927,7641,443,6544,283,712
Operating expenses:Research and development1,166,605843,5491,960,5891,418,228
Operating expenses:Total operating expenses3,035,5125,157,9066,598,8618,729,896
Operating expenses:Operating loss-2,699,733-5,157,906-6,209,232-8,729,223
Non-operating income (expense):Change in fair value of warrant liability76,12210,910722,108
Non-operating income (expense):Change in fair value of derivative liability-662,916-59,594
Non-operating income (expense):Loss on conversion of note payable-96,646
Non-operating income (expense):Loss on disposition of subsidiaries-385,528-385,528
Non-operating income (expense):Interest income147,14763,148280,49188,590
Non-operating income (expense):Interest expense-269,785-653,493-306,804-1,324,277
Non-operating income (expense):Total non-operating expense-122,638-1,562,667-15,403-1,055,347
Non-operating income (expense):Net loss-2,822,371-6,720,573-6,224,635-9,784,570
Net loss per common shareBasic-0.07-0.48-0.16-0.83
Net loss per common shareDiluted-0.07-0.48-0.16-0.83
Weighted average common shares outstandingBasic39,615,81514,141,44339,615,81511,844,024
Weighted average common shares outstandingDiluted39,615,81514,141,44339,615,81511,844,024

Balance Sheet

June 30, 2026 — (Unaudited)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents8,188,1406,662,008
Current assets:Accounts receivable, net385,313731,328
Current assets:Inventory203,074213,408
Current assets:Prepaid expenses425,370262,278
Current assets:Deferred offering costs47,384
Current assets:Total current assets9,201,8977,916,406
Current assets:Restricted cash3,012,271
Current assets:Property, plant and equipment, net14,50015,500
Current assets:Notes receivable5,000,0005,000,000
Current assets:Interest receivable437,500250,000
Current assets:Intangible assets, net70,065,37170,973,064
Current assets:Operating lease right-of-use assets2,46823,360
Current assets:Total assets87,734,00784,178,330
Current liabilities:Accounts payable916,7711,443,266
Current liabilities:Accrued liabilities503,634657,034
Current liabilities:Operating lease liability - current2,54624,137
Current liabilities:Warrant liability10,914
Current liabilities:Note payable, net of debt discount - current portion1,118,349
Current liabilities:Development agreement liability - current portion485,000600,000
Current liabilities:Total current liabilities3,026,3002,735,351
Current liabilities:Note payable, net of debt discount9,568,586
Current liabilities:Development agreement liability285,000
Current liabilities:Deferred tax liability11,037,59511,037,595
Current liabilities:Total liabilities23,632,48114,057,946
Stockholders’ equity:Common stock, $0.00001 par value; 100,000,000 shares authorized; 41,064,146 and 40,630,815 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 1,448,331 and 1,015,000 shares unvested as of June 30, 2026 and December 31, 2025, respectively410406
Stockholders’ equity:Additional paid-in capital150,876,988150,671,215
Stockholders’ equity:Accumulated deficit-86,775,872-80,551,237
Stockholders’ equity:Total stockholders’ equity64,101,52670,120,384
Stockholders’ equity:Total liabilities and stockholders’ equity87,734,00784,178,330
Full release

Statements Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange

Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, such as Arbli™ and REZENOPY™, and our strategies related to those products.

In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”

“intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,”

“should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on

Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Contact

:

SCIENTURE

HOLDINGS, INC.²⁰

Austin Blvd

Commack,

NY 11725

Email:

IR@Scienture.com

Scienture

Holdings, Inc. formerly TRxADE HEALTH, INC.

Condensed

Consolidated Balance Sheets

As of June 30, 2026 and December 31, 2025

(Unaudited)..enture

Holdings, Inc. formerly TRxADE HEALTH, INC.

Condensed Consolidated Statements Of Operations

For the Three and Six Months Ended June 30, 2026 and 2025

(Unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Scienture Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.